bims-fagtap Biomed News
on Phage therapies and applications
Issue of 2026–03–29
forty-four papers selected by
Luca Bolliger, lxBio



  1. Viruses. 2026 Mar 13. pii: 355. [Epub ahead of print]18(3):
      The escalating crisis of antimicrobial resistance (AMR) and the stagnating antibiotic pipeline have renewed interest in bacteriophage therapy. While natural phages offer specificity and low toxicity, their narrow host range, bacterial resistance, and safety concerns limit clinical use. To overcome these hurdles, phages are being engineered using biotechnology. This review outlines the history of phage therapy and systematically summarizes advances in engineered phage preparation, including genetic modification, chemical conjugation, and physical encapsulation. We highlight the application of engineered phages against multidrug-resistant infections, gastrointestinal diseases through gut microbiome modulation, and as targeted delivery vehicles or immune adjuvants in cancer therapy. While significant advances have been made, several critical challenges remain, particularly in regulatory approval, large-scale manufacturing, and ensuring long-term safety. We conclude that engineered phages, as customizable and precise biological tools, are poised to advance precision phage medicine, offering a transformative solution to AMR and fostering convergence across synthetic biology, medicine, and environmental science.
    Keywords:  bacteriophage; engineered phages; phage therapy; precision medicine; synthetic biology
    DOI:  https://doi.org/10.3390/v18030355
  2. Respir Med. 2026 Mar 24. pii: S0954-6111(26)00157-5. [Epub ahead of print]256 108789
       OBJECTIVE: Inhaled bacteriophage therapy is an emerging adjunctive strategy for treating lower respiratory tract infections caused by multidrug-resistant (MDR) pathogens. However, the clinical evidence base remains fragmented. We conducted a scoping review to map the current landscape of human studies using nebulized, aerosolized, or dry-powder phage therapy for pulmonary infections.
    METHODS: We systematically searched PubMed, Scopus, Web of Science, and ClinicalTrials.gov for clinical studies published up to 1 June 2025. Eligible studies included clinical trials, cohort studies, and case reports/series reporting at least one dose of inhaled lytic phage for bacterial respiratory infections. Screening followed PRISMA-ScR guidelines. Key data were extracted on patient characteristics, pathogens, phage preparations, delivery methods, safety, and outcomes.
    RESULTS: Of 507 records identified, 31 studies met inclusion criteria: six clinical trials and 25 case reports or series. Target infections included ventilator-associated pneumonia, cystic fibrosis exacerbations, and chronic bronchiectasis, primarily due to Pseudomonas aeruginosa, Acinetobacter baumannii, or Klebsiella pneumoniae. Delivery methods varied widely, including nebulizers, dry-powder inhalers, and endotracheal instillation. Most studies reported clinical or microbiological improvement without major adverse events, though few used standardized outcome measures.
    CONCLUSIONS: Inhaled phage therapy has shown promise in compassionate and investigational settings for MDR respiratory infections. Despite heterogeneity in delivery methods and outcome reporting, preliminary data suggests feasibility and safety. Standardized protocols and controlled trials are needed to define its role in pulmonary antimicrobial therapy.
    Keywords:  Bacteriophage therapy; Inhalation delivery; Multidrug-resistant pathogens; Pulmonary infections
    DOI:  https://doi.org/10.1016/j.rmed.2026.108789
  3. Int J Infect Dis. 2026 Mar 23. pii: S1201-9712(26)00216-X. [Epub ahead of print] 108581
       BACKGROUND: Despite advances in cystic fibrosis management, chronic infections caused by multidrug-resistant bacteria remain a major clinical challenge. Bacteriophage therapy, which uses viruses that selectively infect and lyse bacteria while sparing host cells, has emerged as a promising approach against biofilm-associated and/or multidrug-resistant pathogens, although current clinical evidence is still limited.
    METHODS: A systematic review was conducted in four major databases up to December 2025 for randomized controlled trials, case reports and case series reporting outcomes in cystic fibrosis patients receiving phage therapy, focusing on microbiological outcomes, changes in forced expiratory volume in one second (FEV₁) and adverse events.
    RESULTS: Nineteen studies involving 51 cystic fibrosis patients and 52 phage treatment courses were analyzed. Pseudomonas aeruginosa was the predominant target (46%). Overall microbiological improvement with bacterial load reduction was achieved in 35/51 cases (68.6%), while FEV1 improvement was documented in 74% (20/27). Safety profile was favorable, with 41 of 52 patients experiencing no adverse events. Two serious adverse events were reported, with uncertain association with phage therapy. Stratified analysis suggests similar results in pediatric and adult efficacy outcomes.
    DISCUSSION AND CONCLUSIONS: Phage therapy appears generally safe and well tolerated in cystic fibrosis patients, with severe adverse events being rare but worthy of attention. Clinical and microbiological improvements were observed in most patients. Evidence of synergistic effects with antibiotics and variable immune responses highlight the complexity of treatment. Considering protocol heterogeneity and small sample sizes, these findings support further well-designed studies to optimize safety and efficacy.
    TRIAL REGISTRATION: PROSPERO 2025 CRD420251135925.
    Keywords:  Multidrug resistance; Pseudomonas aeruginosa; efficacy; outcome; safety
    DOI:  https://doi.org/10.1016/j.ijid.2026.108581
  4. Antibiotics (Basel). 2026 Mar 20. pii: 317. [Epub ahead of print]15(3):
      Shigellosis remains a significant global cause of infectious colitis, increasingly complicated by multidrug-resistant strains and the microbiota-disrupting effects of broad-spectrum antibiotics. Although conventional antimicrobial therapy can reduce symptom duration and bacterial shedding, it also contributes to gut dysbiosis, loss of colonization resistance, and further selection for antimicrobial resistance. These challenges have renewed interest in precision antimicrobial strategies, particularly bacteriophage therapy, which provides strain-level specificity and preserves the gut microbiota. This narrative review evaluates the biological rationale, preclinical and early clinical evidence, safety considerations, and translational challenges associated with bacteriophage therapy targeting Shigella spp. The historical development and mechanistic basis of phage therapy are summarized, with emphasis on the advantages of obligately lytic phages, receptor-specific targeting, self-amplification at infection sites, and activity against both planktonic and biofilm-associated bacteria. Recent microbiota research indicates that shigellosis is closely associated with early and persistent disruption of gut ecology, including depletion of short-chain fatty acids-producing taxa and reduced microbial resilience. Phage-based approaches may reduce pathogen burden while preserving beneficial microbial communities. Evidence from in vitro systems, animal models, human intestinal organoids, and a Phase 1 clinical trial demonstrates targeted efficacy and favorable safety profiles for Shigella-specific phages and phage cocktails. Major barriers to clinical adoption include immune interactions, phage resistance dynamics, genomic safety screening, regulatory classification, and the need for standardized susceptibility testing. Future directions emphasize the development of personalized phage therapy platforms that integrate rapid diagnostics, phage libraries, metagenomics, and artificial intelligence-assisted matching to enable scalable, precision treatment.
    Keywords:  infection; management; precision medicine; treatment
    DOI:  https://doi.org/10.3390/antibiotics15030317
  5. Pharmaceutics. 2026 Mar 20. pii: 387. [Epub ahead of print]18(3):
      Respiratory infections remain a significant global health concern, especially as multidrug-resistant (MDR) respiratory pathogens reduce the effectiveness of conventional antibiotics. Patients with chronic lung diseases face persistent biofilm-related infections that are difficult to treat, underscoring the urgency for new solutions. This challenge has renewed focus on bacteriophage therapy as a promising alternative in respiratory antimicrobial management. Bacteriophages are viruses that selectively infect and lyse bacteria, showing strong potential as a precise and effective therapy for resistant pulmonary infections. This review focuses on the mechanisms of phage biology and therapy in lung infections, highlighting their unique interactions with mucus, surfactants, and immune defenses-all of which are central to their clinical promise. The review examines advances in phage engineering, delivery strategies, and inhaled formulations aimed at maximizing phage stability and targeting within the airways. It summarizes recent preclinical and clinical progress targeting MDR respiratory pathogens and discusses regulatory, manufacturing, and safety considerations key to integrating phage therapy into mainstream respiratory care.
    Keywords:  antibiotic; bacteriophage; lung; multidrug-resistant; respiratory infection
    DOI:  https://doi.org/10.3390/pharmaceutics18030387
  6. Nurs Stand. 2026 Mar 23.
      Chronic wounds present numerous challenges for patients and for healthcare systems, including longer hospital stays, pain and discomfort, and increased use of resources and related financial costs. For nurses, chronic wound management can be difficult and sometimes confusing, particularly given the wide range of available products and uncertainty about which is the most appropriate product to use. This article provides an overview of chronic wounds, including the effects on patients and healthcare systems, definitions, risk factors and common types of chronic wounds, and some of the challenges of wound management for nurses. The article also describes some emerging innovations in wound care, including digital wound technologies and regenerative treatments, and outlines their benefits for nursing practice and patients.
    Keywords:  chronic wounds; clinical; diabetic foot ulcers; innovation; leg ulcers; pressure ulcers; skin; telehealth; wound care; wound care products; wound healing; wound management
    DOI:  https://doi.org/10.7748/ns.2026.e12649
  7. Annu Rev Virol. 2026 Mar 25.
      Despite progress in controlling microbial infections, the global burden of pathogenic bacteria remains high. Moreover, the spread of antibiotic-resistant bacteria has increased and is likely to continue. Consequently, recent research has focused on antibiotic alternatives to slow the proliferation of resistance and improve patient outcomes. One promising approach is phage therapy, which uses lytic viruses of bacteria to treat bacterial infections. However, an underexplored potential benefit is its capacity to enhance health outcomes across the socioeconomic spectrum and improve healthcare equity. Drawing on the history of phage therapy, recent clinical successes, and advancements in research, we argue that phage therapy is well-suited to advance health and healthcare equity. This is because it offers a comparatively greater potential to increase access and reduce disadvantages faced by lower socioeconomic groups relative to conventional antibiotics. Based on these points, we propose research objectives that aim to achieve these scientific and ethical goals.
    DOI:  https://doi.org/10.1146/annurev-virology-092623-110310
  8. Stud Hist Philos Sci. 2026 Mar 20. pii: S0039-3681(26)00036-1. [Epub ahead of print]117 102150
      This article proposes a conceptual analysis of Chang's notion of complementary science through a case study on the revival of phage therapy. Complementary science urges historians and philosophers to recover and extend Kuhn losses - prematurely abandoned systems of practice. The revival of phage therapy, which involves aligning not only epistemic but also material, social, regulatory and clinical elements, reveals the need to extend Chang's framework with Ankeny and Leonelli's notion of repertoires. This conceptual shift proves broadly fruitful. For complementary science, it highlights the normative and ethical dimensions involved in identifying Kuhn losses and foregrounds its transdisciplinary nature. It also clarifies how established repertoires can function both as ambivalent inspirations and entrenched obstacles for emerging ones. Finally, it helps reframe the historical trajectory and contemporary assessment of phage therapy, showing a plurality of benefits and of possible developments independently of its full reintegration into the Western pharmacopoeia. More generally, the article illustrates the value of an integrated history and philosophy of science attentive to the interlinked material, epistemic and social elements involved in scientific practices.
    Keywords:  Complementary science; Evidence-based medicine; Integrated history and philosophy of science; Phage therapy; Repertoires; Scientific pluralism
    DOI:  https://doi.org/10.1016/j.shpsa.2026.102150
  9. World J Virol. 2026 Mar 25. 15(1): 118362
      Paediatric gut microbiome research has long been bacteriocentric, overlooking the extensive viral component known as the gut virome. Composed of bacteriophages, eukaryotic viruses, and endogenous viral elements, the paediatric gut virome is the most abundant and genetically diverse biological entity in the intestine. Emerging evidence indicates that the virome is a key regulator of microbial ecology, immune maturation, and systemic physiological programming during early life. This narrative review synthesizes current knowledge on the establishment, development, and functional roles of the paediatric gut virome, with emphasis on its interactions with the bacterial microbiome and host immune system. We highlight how early-life viral exposures influence mucosal immune imprinting, epithelial barrier integrity, and immune tolerance, particularly during the first 1000 days of life. Virome dysbiosis is increasingly associated with paediatric gastrointestinal disorders, including inflammatory bowel disease, necrotizing enterocolitis, celiac disease, and functional gastrointestinal disorders. Beyond the gut, the virome also contributes to metabolic regulation, type 1 diabetes risk, and gut-brain axis signaling, influencing neurodevelopment. Mechanistic pathways involving phage-mediated bacterial modulation, innate immune sensing, cytokine signaling, and metabolic intermediates are discussed, positioning the paediatric gut virome as a central regulator of gastrointestinal and systemic homeostasis.
    Keywords:  Bacteriophages; Dysbiosis; Gut-immune axis; Microbial succession; Necrotizing enterocolitis; Paediatric virome; Phage therapy
    DOI:  https://doi.org/10.5501/wjv.v15.i1.118362
  10. Front Cell Infect Microbiol. 2026 ;16 1750702
      In the modern era, the expanding demand for implants has transformed the healthcare system by restoring and enhancing the function of various biological structures, thereby increasing the patients' quality of life. These include urinary catheters, dental, orthopedic, cardiovascular implants, and sutures designed to perform various functions. However, these devices are more prone to microbial attack, contributing to biofilm formation mainly caused by multidrug-resistant ESKAPE pathogens, thereby increasing the risk of implant-associated infections and implant failure. This review summarizes the diverse array of implants available on the market and their associated infections caused by biofilm-producing pathogens, with a particular emphasis on the ESKAPE pathogen. Specific keywords were used to conduct a literature review using Google Scholar, Web of Science, PubMed, and Scopus databases. The data were then screened and integrated to explore the underlying principles of biofilm formation, its consequences, diagnostic approaches, and therapeutic studies. Currently, various methods are employed to diagnose these infections, including culture-based methods (tissue swab, culture, sonication) and non-culture methods (Dithiothreitol, XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide), Resazurin, BioTimer assays, and PCR). However, these studies indicate an increased difficulty in detecting infections caused by ESKAPE pathogens due to biofilm formation, highlighting the need for developing novel strategies. The recent advancements in the development of antimicrobial coatings, implant surface modifications, phage therapy, nanoparticles, antimicrobial peptides, and quorum-sensing inhibitors have shown promise in controlling these infections. Thus, these findings underscore the importance of research on innovative approaches and the development of infection-resistant implants, thereby reducing the clinical burden and improving patient outcomes.
    Keywords:  ESKAPE pathogens; biomaterials; implant-associated infection; implants; microbial biofilm; quorum sensing
    DOI:  https://doi.org/10.3389/fcimb.2026.1750702
  11. Microbiol Spectr. 2026 Mar 23. e0264025
      Phage therapy, despite its promise as a novel therapeutic alternative for multidrug-resistant (MDR) bacterial infections, is hampered by clinical limitations such as narrow host range and therapeutic inconsistency. This research has engineered a phage-antibiotic synergistic therapy enabling precision eradication of drug-resistant Salmonella Typhimurium (S. Typhimurium). From slaughterhouse wastewater and fecal samples, three Felixounavirus phages (TSP_TW2, TSP_SW1, and TSP_SJ5) were isolated. Compared to the clinical phage repository, these phages demonstrated more superior broad-spectrum activity, successfully lysing over 85% of the tested wild-type isolates. The in vitro study, validated by laser confocal fluorescence imaging demonstrates that compared to solitary phage, phage cocktail delays the emergence of resistance to 24 h while also achieving effective biofilm eradication. In the murine intestinal infection model, the experimental group treated with phage cocktail in combination with ciprofloxacin (CIP) demonstrated significant therapeutic effects, reaching 90% survival rate, restoring the CD4+/CD8+ T cell balance, and decreasing the levels of pro-inflammatory factors, which were significantly superior to those of phage or CIP alone. In addition, the susceptibility of S. Typhimurium to β-lactams, quinolones, and observed four- to eightfold reduction in tetracycline minimal inhibitory concentration (MIC) demonstrated effective restoration of antibacterial activity after therapeutic intervention. 16S rRNA high-throughput sequencing showed that the index of intestinal flora diversity of mice in the treatment group was not significantly difference to healthy control group, while specifically promoting the growth of beneficial microbial populations such as Lactobacillus spp. The innovative phage-antibiotic combination therapy established in this study demonstrated dual therapeutic advantages: effective clearance of antimicrobial-resistant strains and maintenance of enteric microbiome homeostasis, thereby offering a clinically promising strategy for controlling infections caused by antimicrobial-resistant S. Typhimurium.IMPORTANCEFoodborne Salmonella infections threaten global public health, as conventional antibiotics accelerate resistance and disrupt microbial balance. We pioneer a synergistic phage-ciprofloxacin cocktail strategy that overcomes multidrug-resistant Salmonella infection through three key advances: First, it delays resistance evolution while eradicating biofilm matrices; second, the therapy synergistically enhances antibiotic sensitivity to restore efficacy of critical drugs; and third, the combined approach maintains optimal gut microbiota balance during pathogen clearance. By using environmentally derived phages with minimized antibiotic dosing, this strategy achieves targeted removal of resistant pathogens-including invasive biofilms-without collateral damage to commensal flora. Crucially, it prevents systemic inflammation and preserves intestinal barrier function. This ecologically sustainable paradigm provides a dual-defense mechanism against infections and microbiome dysbiosis, positioning phage-antibiotic synergy as a transformative tool for containing foodborne disease threats.
    Keywords:  S. Typhimurium; gut microbiota; intestinal inflammation; phage cocktail-CIP
    DOI:  https://doi.org/10.1128/spectrum.02640-25
  12. Microorganisms. 2026 Feb 27. pii: 549. [Epub ahead of print]14(3):
      Infections caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA), especially chronic infections associated with biofilm formation, have become a major clinical challenge. Phage therapy has received much attention as an alternative strategy, but temperate phages have limited direct application due to their lysogenicity. The aim of this study was to explore the synergistic therapeutic effect of a novel temperate phage combined with antibiotics. A temperate Pseudomonas phage YF1204 was isolated from the patient's bronchoalveolar lavage fluid and systematically characterized by whole-genome sequencing, transmission electron microscopy, and host range analysis. The synergistic antibacterial and anti-biofilm effects of phage with amikacin (AK) were evaluated by using the checkerboard test, a time-killing curve based on optical density (OD600) and crystal violet staining, and the cytocompatibility was analyzed by using the CCK-8 method. The results showed that phage YF1204 belonged to the Siphoviridae family and had typical temperate phage genome characteristics (containing integrase gene). It also showed lytic activity against 41.4% (87/210) of the clinical isolates, especially against carbapenem-resistant strains. When YF1204 was combined with AK, it reduced the minimum inhibitory concentration (MIC) of AK by 2- to 8-fold across all tested strains, respectively. Moreover, the inhibitory effect against CRPA was significantly enhanced (achieving suppression indexes about 80% ) and biofilm formation was inhibited with an inhibition ratio of 48.75%. Cell experiments showed that YF1204 had no significant toxicity to THP-1 cells. The combination of YF1204 and AK exhibited significant synergistic bactericidal and anti-biofilm activities, providing a novel therapeutic strategy with translational potential for CRPA-induced refractory infections.
    Keywords:  Pseudomonas aeruginosa; amikacin; carbapenem resistance; phage-antibiotic synergy; temperate bacteriophage
    DOI:  https://doi.org/10.3390/microorganisms14030549
  13. Biofilm. 2026 Jun;11 100358
      Antimicrobial resistance (AMR) is a great global health threat, with biofilm formation recognized as a key microbial survival strategy that promotes persistence and recurrent infections. Despite growing mechanistic insights, research on biofilm-associated AMR ((biofilm-AMR)) remains fragmented, limiting the development of broadly effective interventions. To address this gap, we conducted a bibliometric analysis of 17,198 publications from the Web of Science Core Collection (retrieved November 4, 2025) using Bibliometrix-Biblioshiny, CiteSpace, and Excel. Publication output accelerated sharply after 2015, alongside diversification of research themes and increasing interdisciplinary integration. High-output countries and institutions, predominantly in Asia, Latin America, and the Middle East, emphasize natural products, nanomaterials, anti-quorum-sensing strategies, and plant-derived antimicrobials, reflecting application-oriented approaches. In contrast, high-impact contributors in North America and Europe focus on clinical microbiology, resistance mechanisms, pathogen genomics, and hospital infection control, highlighting translational relevance. Trend analyses reveal key topics including quorum sensing, persister-cell biology, multidrug-resistant pathogens, and innovative interventions such as phage therapy, antimicrobial peptides, CRISPR-based antimicrobials, and nanotechnology-enabled drug delivery. Emerging directions include environmental AMR, One Health perspectives, and computational modeling. Despite mechanistic and technological advances, translational barriers persist due to biofilm heterogeneity and model limitations. Promoting interdisciplinary collaboration that integrates basic research, clinical microbiology, materials science, and computational approaches will be essential to accelerate clinical translation and develop effective, globally relevant strategies against AMR.
    Keywords:  Anti-biofilm therapeutics; Antimicrobial resistance (AMR); Bibliometric analysis; Biofilm; Global health
    DOI:  https://doi.org/10.1016/j.bioflm.2026.100358
  14. Khirurgiia (Mosk). 2026 ; 106-122
       BACKGROUND: In conditions of increasing bacterial resistance to antibiotics, bacteriophages are becoming particularly important as a promising tool for combating surgical infection of the skin and soft tissues. Scientific studies in recent years have demonstrated the effectiveness of phage therapy both as a treatment method and in order to prevent the development of nosocomial infectious complications, including infections caused by multidrug-resistant strains of microorganisms.
    OBJECTIVE: The aim of the study was a comparative clinical, cytomorphological and microbiological analysis of the efficacy and safety of phage therapy in the treatment of purulent wounds of various etiologies and localization in patients over 18 years of age.
    MATERIALS AND METHODS: The article presents the results of a prospective randomized comparative clinical trial of 80 adult patients with purulent wounds of various etiologies and localization treated at the Department of Wounds and Wound Infections of the A.V. Vishnevsky National Medical Research Center of Surgery of the Ministry of Health of the Russian Federation in 2022-2024 (LEK conclusion No. 7/2NIR-22 dated 05/31/2022). During the study, clinical (edema, pain, the nature of wound discharge, the appearance of granulation tissue), laboratory (the presence and regression of signs of a systemic inflammatory response to the presence of a surgical infection), microbiological (qualitative and quantitative), cytological and morphological parameters were analyzed in all patients. Parametric data were evaluated based on the mean and standard deviation (SD) at 4 study points: point 1 (1±1 day), point 2 (3±1 day), point 3 (7±1 day) and point 4 (9±1 day) after surgical treatment of the purulent focus. The key endpoint was the transition of the wound healing process into the regeneration phase.
    RESULTS: According to the study protocol, all the patients included in the analysis had purulent-necrotic wounds of soft tissues and bones of different etiology and localization, requiring surgical treatment. To distribute patients into groups, upon admission or intraoperatively, material was collected for qualitative and quantitative microbiological, cytological, morphological and electron microscopic studies. Randomization was carried out using the pseudorandomization method, patients were selected in a 1:1 ratio based on an assessment of the sensitivity of isolated cultures to the drug "Piobacteriophage complex" liquid (Piophage, NPO Microgen JSC, Russia). In the postoperative period, patients of group I (n=20) received systemic and local phage therapy (20 ml 3 times per day, according to the instructions); in subgroup Ia (n=20), bacteriophages were delivered to the focus using negative pressure devices with instillation (-120 mm Hg, permanent mode, VitMedical, Russia); in group II (n=20), systemic and local antibacterial therapy was performed; in group III (n=20)- systemic treatment with local negative pressure (-120 mmHg, permanent mode, VitMedical, Russia).
    An analysis of the treatment results indicates the high effectiveness of the proposed protocol in all study groups. In group 1a (local negative pressure with bacteriophage instillation in combination with systemic phage therapy) The best microbiological, cytological, morphological and clinical efficacy was noted, indicating the potentiation of both methods of treating purulent wounds of various etiology and localization (the first signs of relief of the inflammatory phase were noted by 3±1 days after surgery). In general, key endpoints (the transition of the wound healing process to the regeneration phase) were achieved in all the studied groups with good tolerability of therapy and a high safety profile. No additional surgical interventions were required in any group, and no deaths were reported. No adverse events requiring discontinuation or change of treatment option were identified.
    CONCLUSION: The principles of purulent wounds treatment in our country are based on the method of active surgical treatment developed in the Department of Wounds and Wound Infections of the Vishnevsky Institute of Surgery (now the Vishnevsky National Research Medical Center of Surgery of the Ministry of Health of the Russian Federation). The results of treatment largely depend on the radicality and thoroughness of the primary surgical debridement of the purulent focus, general and local treatment in the perioperative period. The inclusion of bacteriophages in treatment regimens, especially in combination with local negative pressure, allows for a more pronounced antimicrobial and regenerative effect, which makes this approach promising in the treatment of purulent-inflammatory diseases. The combination of active surgical treatment with local negative pressure therapy and bacteriophage instillation demonstrates pronounced synergy: surgical treatment of purulent wounds reduces microbial contamination and destroys biofilms, which increases the availability of phages. In turn, their bacteriolytic and bacteriostatic activity prevents re-colonization and promotes the transition of the wound process to the regeneration phase, which is especially important in the presence of polyresistance.
    Keywords:  Pyophage; bacteriophages; fluoroquinolones; instillation; local negative pressure; local treatment; ointments based on polyethylene glycol; purulent wound; surgical infection; surgical treatment
    DOI:  https://doi.org/10.17116/hirurgia2026031106
  15. Int J Mol Sci. 2026 Mar 20. pii: 2826. [Epub ahead of print]27(6):
      Diabetic foot ulcers (DFUs) are among the most serious and costly complications of diabetes, characterised by delayed healing, frequent infections, and a high risk of recurrence. Despite advances in wound care, many current therapies fail to address the multifactorial pathophysiology of diabetic wounds, including vascular dysfunction, immune dysregulation, chronic inflammation, and microbial imbalance. In this context, topical probiotics have emerged as a promising microbiome-based strategy aimed at restoring microbial balance while promoting tissue repair. This review summarises current evidence on the use of topical probiotics in diabetic wound healing, with a particular focus on DFUs, outlining key pathophysiological barriers to healing and examining how probiotic therapies may counteract these processes through antimicrobial, antibiofilm, immunomodulatory, and pro-angiogenic mechanisms. Preclinical studies suggest that topical probiotics may promote accelerated wound closure, reduce bacterial burden, modulate inflammatory responses, and enhance collagen deposition and angiogenesis following topical probiotic application. Early clinical studies investigations remain limited to small pilot studies and case series but have reported preliminary signals of enhanced healing and acceptable short-term tolerability in small exploratory cohorts. In addition, recent advances in probiotic delivery, such as bioengineered dressings, postbiotic formulations, and nano-enabled systems designed to improve stability and therapeutic performance, are also discussed. While existing data indicate biological plausibility and early clinical feasibility, larger, well-designed randomized controlled trials and deeper mechanistic investigations are still required to confirm efficacy, clarify safety in high-risk populations, and enable responsible clinical translation.
    Keywords:  angiogenesis; biofilms; diabetic foot ulcers; inflammation; skin microbiome; topical probiotics; wound healing
    DOI:  https://doi.org/10.3390/ijms27062826
  16. Int J Mol Sci. 2026 Mar 18. pii: 2766. [Epub ahead of print]27(6):
      Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by cholestasis, which can progress to end-stage liver disease and even hepatocellular carcinoma. Its onset is typically triggered by complex interactions between genetic and environmental factors. In recent years, epidemiological and mechanistic studies have highlighted bacterial and fungal infections as potential key environmental factors in PBC pathogenesis. Bacteria may be associated with PBC autoimmunity through mechanisms such as molecular mimicry. Gut microbiota dysbiosis has been linked to aberrant immune recognition, altered metabolites, and intestinal barrier disruption, which may contribute to the aggravation of liver injury. Case reports of fungal infections suggest an association with poor prognosis in PBC, although the underlying mechanisms remain to be elucidated. This review systematically summarizes existing clinical epidemiological data, microbiome association studies, and mechanistic evidence; synthesizes the possible molecular mechanisms linking bacterial infections to PBC development and progression; discusses the potential role of the gut microbiota in PBC progression; and analyzes the possible molecular mechanisms underlying the poor prognosis associated with fungal infections in PBC. This study aims to provide valuable insights for developing optimal prevention, diagnosis, and treatment strategies targeting bacterial and fungal infections in PBC.
    Keywords:  bacterial infection; fungal infection; pathogenesis; primary biliary cholangitis
    DOI:  https://doi.org/10.3390/ijms27062766
  17. Microorganisms. 2026 Mar 12. pii: 641. [Epub ahead of print]14(3):
      Porphyromonas gingivalis is described as a keystone pathogen associated with periodontal disease (PD), which exhibits enhanced representation upon microbial dysbiosis in such a chronic inflammatory disease. This oral pathogen drives and contributes to a dysregulated immune response, resulting in stages of aggressive destructive immune activation and inflammation punctuated by immune suppression, which underlies the relapsing-remitting nature of this disease. The understanding of key mechanisms and balance between protective innate, adaptive immune responses and dysregulated responses, linked to changes in the oral mucosal microbial environment, will afford researchers the potential to manipulate oral mucosal environments for clinical benefit. This review focuses on the dynamic interactions between the oral pathogen P. gingivalis and the immune system with an emphasis on immune evasion and how the potential correction of these mechanisms may benefit future therapeutic interventions, leading to the successful treatment of PD.
    Keywords:  Porphyromonas gingivalis; dysbiosis; endotoxin tolerization; immune evasion; inflammation; periodontal disease
    DOI:  https://doi.org/10.3390/microorganisms14030641
  18. Microb Pathog. 2026 Mar 25. pii: S0882-4010(26)00195-6. [Epub ahead of print] 108469
      Proteus mirabilis is an opportunistic pathogen frequently associated with catheter-associated urinary tract infections, where robust crystalline biofilms contribute to chronicity, antimicrobial tolerance, and recurrence. The rising prevalence of multidrug-resistant (MDR) P. mirabilis has prompted interest in bacteriophage therapy as an alternative to conventional antibiotics. In this study, we isolated a lytic bacteriophage, vB_PmiM_ZX7, from sewage using a highly virulent clinical strain, P. mirabilis YV2, as the host. vB_PmiM_ZX7 displayed a broad host range among MDR P. mirabilis isolates and tolerance to a wide range of pH and temperatures. Genome sequencing revealed 60% of genes with unknown function, absence of virulence or antibiotic resistance genes, and limited similarity to known P. mirabilis phages, underscoring its genomic novelty. Safety evaluation in a murine model showed no adverse effect, histopathological changes, or persistent phage accumulation. Circulating phages were cleared from the blood within 5 h and from organs within 48 h. In anti-biofilm assays, vB_PmiM_ZX7 eradicated 62.2% of established biofilms, outperforming piperacillin/tazobactam (TZP), and significantly reduced extracellular polysaccharide content and biofilm density, as confirmed by scanning electron microscopy and fluorescence imaging. Furthermore, ZX7 demonstrated strong anti-biofilm activity in an in vitro catheter-associated biofilm model, markedly reducing the viability of biofilm-associated bacteria in a time-dependent manner. These findings demonstrated the potential of vB_PmiM_ZX7 as a therapeutic candidate for catheter-associated MDR P. mirabilis infections.
    Keywords:  Bacteriophage (phage); Biofilm; Phage therapy; Proteus mirabilis
    DOI:  https://doi.org/10.1016/j.micpath.2026.108469
  19. Pharmaceuticals (Basel). 2026 Feb 25. pii: 363. [Epub ahead of print]19(3):
      Background/Objectives: Bacteriophages offer a promising alternative to conventional antibiotics. However, their therapeutic efficacy is often limited by instability in harsh environmental conditions, particularly within the gastrointestinal tract. This study aimed to isolate lytic bacteriophages from wastewater and evaluate the protective capacity of sodium alginate encapsulation against various stressors to enable effective oral delivery. Methods: Four distinct lytic phages (As, Ec, Pa, Gc) were isolated from wastewater and characterized by Transmission Electron Microscopy (TEM) and PCR, confirming their families (Siphoviridae, Podoviridae, Myoviridae). These phages demonstrated potent lytic activity against diverse bacterial pathogens, including Aeromonas hydrophila, Escherichia coli, Pseudomonas aeruginosa, and Glutamicbacter creatinolyticus. The phages were encapsulated in 5% sodium alginate via an extrusion method. Stability was assessed under extreme pH (2.0 and 13), at elevated temperature (up to 80 °C), and in simulated gastrointestinal transit. Results: Encapsulation efficiency exceeded 95%. Unencapsulated phages were completely inactivated at pH 2.0 within 10 min, whereas encapsulated phages maintained significant viability (3.06-3.43 log PFU/mL). Encapsulation also significantly enhanced phage survival under extreme alkaline conditions and elevated temperatures. In simulated gastrointestinal transit, encapsulated phages exhibited superior recovery (2.50 log PFU/mL) compared to their free counterparts (≤1 log PFU/mL). Long-term storage evaluations over three months further confirmed the robust stability of the encapsulated formulations at both 4 °C and 21 °C. Conclusions: Sodium alginate encapsulation effectively shields bacteriophages from severe environmental degradation, particularly acidic gastric stress, enhancing their potential for oral delivery. These findings support the development of stable, formulated phage products for diverse practical applications in phage therapy to combat antimicrobial resistance.
    Keywords:  alginate beads; bacteriophage therapy; encapsulation efficiency; oral phage delivery; phage encapsulation; phage viability; simulated gastrointestinal conditions
    DOI:  https://doi.org/10.3390/ph19030363
  20. Microbiology (Reading). 2026 Mar;172(3):
      Chronic infection by opportunistic pathogens is a major contributor to mortality in people with cystic fibrosis (CF). These infections are caused by antimicrobial-resistant pathogens such as the emerging pathogen, Mycobacterium abscessus, a nontuberculous mycobacteria which causes recalcitrant infections with high resistance to antibiotics. M. abscessus adapts over time of colonisation to the conditions in the CF lung, hampering effective treatment. The mechanisms underlying this pathoadaptation are poorly understood and are critical for the development of future therapies. Sequential isolate pairs of M. abscessus from three people with CF were examined for adaptive changes over time of infection. These isolate pairs range in time span from 33 to 295 days. Genomic analysis confirmed that these isolate pairs were clonal. The late infection isolates showed increased host cell attachment to CF bronchial epithelial cells, and one late isolate showed increased intracellular survival in macrophages, indicative of potential adaptation to the CF lung environment. Late isolates also showed changes in their proteomes, including changes in abundance of proteins with roles in intracellular survival and antibiotic resistance. Overall, it is clear that M. abscessus can adapt to the CF lung environment and improve its ability to interact with host cells.
    Keywords:  Mycobacterium abscessus; adaptation; antibiotic resistance; chronic infection; cystic fibrosis; hypoxia; lung disease
    DOI:  https://doi.org/10.1099/mic.0.001677
  21. Biomedicines. 2026 Mar 17. pii: 697. [Epub ahead of print]14(3):
      Fusobacterium species, particularly Fusobacterium nucleatum, is known as a key adhesive bridging microorganism in the development of periodontal disease, inducing microbial imbalances and chronic inflammation within the oral cavity. Their role is to provide a bridge between both early colonisers (such as Streptococcus and Actinomyces) and late colonisers (such as Porphyromonas gingivalis and Treponema denticola), which results in multispecies biofilm formation. This triggers an immune reaction which may provide both a protective and destructive effect on the periodontal ligament and alveolar bone. Recent studies have discovered their significance beyond oral pathology. Therefore, Fusobacterium have been implicated in several systemic diseases, including cardiovascular disease (CVD). Virulent mechanisms, such as adhesion, invasion, modulation of host immunity, and pro-inflammatory signalling, contributes to periodontal tissue bone loss and entry into the circulation. Circulating bacteria interact with vascular endothelium and promote atherosclerotic plaque formation. The role of Fusobacterium nucleatum as a microbial link between periodontal disease and cardiovascular disease is highlighted and discussed. Overall, current evidence is mostly observational and preclinical, supporting an associative link between F. nucleatum-mediated periodontal disease and CVD. The literature highlights key mechanistic pathways while underscoring the important need for longitudinal studies to clarify causality and identify target therapeutic interventions.
    Keywords:  Fusobacterium nucleatum; cardiovascular disease; microbial imbalances; oral microbiome; periodontal disease; systemic inflammation
    DOI:  https://doi.org/10.3390/biomedicines14030697
  22. Nanomedicine (Lond). 2026 Mar 23. 1-23
      Small molecule modulators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) play a key role in cystic fibrosis (CF) management. Around 10% of people with CF (pwCF), however, are ineligible for modulator therapy. Inhalable CFTR gene and RNA therapies have the potential to return normal CFTR function to the lungs and provide a viable alternative therapy for all pwCF, regardless of mutation. Since 1993, 22 clinical trials of CF gene and RNA therapies based on viral and non-viral vectors have been undertaken, along with many more pre-clinical studies. To date, however, no single system has shown sufficient efficacy to warrant translation of this technology into the market. Nevertheless, novel gene carriers for CF treatment are continuously being developed, building upon the outcomes of prior clinical trials and knowledge about how the gene and RNA vectors behave in vivo. Given the suboptimal efficacy observed in humans over the last three decades, this review provides an objective overview of the progress and future of the inhaled delivery technologies that have been examined to date and the observed challenges and benefits of each. This study explored several databases, including PubMed, Scopus, and Google Scholar from January to November 2025.
    Keywords:  Cystic fibrosis; gene therapy; inhalable therapy; lung delivery; nanoparticle; transduction; transfection; virus
    DOI:  https://doi.org/10.1080/17435889.2026.2640157
  23. Medicina (Kaunas). 2026 Feb 28. pii: 468. [Epub ahead of print]62(3):
      Background and Objectives: Assessing the national burden of chronic wounds is a complex data analytics challenge. Robust estimates in Eastern Europe are scarce, highlighting the need for computational methods to validate cases in large-scale health databases. Materials and Methods: We applied a large-scale data analytics approach to Romania's National Inpatient Database (public hospitals, 2017-2022). A computational case-ascertainment algorithm (validated "≥2 admissions" rule) was used to identify recurrently hospitalized patients, establishing a cohort of 18,856 patients (65,771 hospitalizations). We computed annual prevalence, incidence, and mortality per 100,000 adults, stratified by ulcer categories, age, and sex. Results: Hospital-treated prevalence and incidence showed a clear pre-pandemic peak followed by a marked decline in 2020-2021 and only partial rebound by 2022, consistent with pandemic-related disruption of inpatient care. Population-level mortality remained low, but pressure ulcers, although least frequent, accounted for the highest mortality burden. Venous ulcers were the most common category, and the hospital-treated burden was concentrated in adults aged ≥ 65 years and in men. Conclusions: This nationwide data-analytics framework provides the first validated inpatient indicators of chronic ulcer burden in Romania and demonstrates substantial hospital-treated disease burden with pronounced sensitivity to healthcare access constraints. Clinical Implications: The findings can support health-policy and prevention strategies by prioritizing early detection and integrated hospital-community wound care pathways for high-risk groups (men and older adults) and by strengthening outpatient services to reduce avoidable admissions.
    Keywords:  chronic wounds; computational epidemiology; data analytics; health informatics; incidence; mortality; prevalence
    DOI:  https://doi.org/10.3390/medicina62030468
  24. Mater Today Bio. 2025 Dec;35 102298
      Chronic wounds, including diabetic foot ulcers, are notoriously difficult to heal due to their complex pathological microenvironments, which are marked by persistent inflammation and impaired angiogenesis. These challenges place a significant burden on both patients and healthcare systems. Extracellular vesicles (EVs), as natural carriers, can modulate the wound microenvironment and facilitate tissue regeneration by delivering bioactive molecules such as proteins and nucleic acids. EVs offer advantages including low immunogenicity and excellent biocompatibility. However, unmodified EVs face limitations such as low therapeutic payloads, limited targeting capability, and vulnerability to degradation. Building on this foundation, this review provides a detailed overview of the specific roles and mechanisms of EVs in wound healing. It focuses particularly on condition-specific strategies, engineering approaches, and the use of biomaterials to further enhance the therapeutic efficacy of EVs in treating chronic wounds. Finally, we highlight the current challenges faced in the clinical translation of EV-based therapies and propose emerging strategies to address these obstacles, offering new directions for chronic wound management.
    Keywords:  Advanced delivery systems; Biomaterials; Chronic wound healing; Engineered EVs; Extracellular vesicles
    DOI:  https://doi.org/10.1016/j.mtbio.2025.102298
  25. Dent J (Basel). 2026 Mar 17. pii: 172. [Epub ahead of print]14(3):
      Background: The increasing use of electronic cigarettes (ECIGs), especially among youth, has raised concerns about the impact of vaping on oral health. While ECIGs are often marketed as a safer alternative, the existing literature suggests that their use may have detrimental effects on the pulmonary and cardiovascular systems. The oral cavity is the first point of contact for ECIG aerosol, and new reports link vaping to the onset of periodontal disease. It is critical to understand the potential effects of vaping on the oral microbiome, which affects systemic health. This study investigates how flavored E-liquids and commensal bacteria influence the growth of Porphyromonas gingivalis, a periodontal pathobiont, under planktonic and biofilm conditions. Methods: P. gingivalis was grown planktonically in the presence of the supernatants of four streptococcal species (Streptococcus gordonii, Streptococcus intermedius, Streptococcus mitis, and Streptococcus oralis) and flavored E-liquids (tobacco, menthol, cinnamon, strawberry, and blueberry) under anaerobic conditions. Multispecies biofilms, including all the species mentioned above and Fusobacterium nucleatum, were also grown anaerobically and quantified by crystal violet assays, qPCR, and CFU counts. Results: Although E-liquids inhibit P. gingivalis growth under planktonic conditions, the presence of commensal supernatants partially mitigates this effect. However, P. gingivalis growth in multispecies biofilms is increased by E-liquid treatments. Conclusions: This study highlights the enhanced growth of P. gingivalis as part of an oral microbial community in the presence of E-liquids. These results suggest that E-liquid-induced alterations in multispecies biofilms may contribute to the observed dysbiosis in vapers and the associated risk of oral diseases.
    Keywords:  Porphyromonas gingivalis; bacterial growth; bactericidal; biofilms; commensal bacteria; e-liquids; electronic cigarettes; oral cavity; streptococci
    DOI:  https://doi.org/10.3390/dj14030172
  26. Biomedicines. 2026 Mar 17. pii: 694. [Epub ahead of print]14(3):
      Infectious diseases remain a major cause of mortality and disability worldwide. This burden is driven, in part, by antimicrobial resistance (AMR) and the re-emergence of epidemic and pandemic threats, underscoring the need for translational research to address knowledge gaps exposed by recent pandemics. Despite significant advances enabled by antibiotics and antivirals, their effectiveness is increasingly constrained by resistance development, limited pathogen spectra, and prolonged development timelines that fail to keep pace with rapidly shifting epidemiology. Diagnostic limitations impede timely pathogen identification and hinder the development of treatment regimens informed by pathogen mechanisms of action. Severe infections frequently involve dysregulated host responses, including hyperinflammation, inflammasome activation, and endothelial or immunothrombotic injury, which may progress to sepsis, immunoparalysis, or chronic sequelae, highlighting the limitations of pathogen-centered paradigms. Conventional biomarkers and culture-based microbiology are often slow or nonspecific, while molecular assays may not reliably distinguish colonization from active infection or capture host-response heterogeneity shaped by age, immune competence, and disease stage. This review synthesizes mechanistic and translational insights across three interrelated axes: (i) host-pathogen interactions, with a focus on innate immune sensing networks (e.g., Toll-like receptors, inflammasomes, RIG-I-like receptors, and cGAS-STING) and microbial replication and immune evasion strategies; (ii) clinical and public health implications, spanning acute organ dysfunction syndromes, post-acute infection syndromes, and AMR-driven health system strain; and (iii) emerging therapeutics along a continuum of pathogen-, virulence-, host-, and immune-directed approaches. Emphasis is placed on anti-virulence therapeutics, bacteriophage therapy, monoclonal antibodies, and engineered immune modalities within frameworks of quantitative translational pharmacology and implementation science. Finally, an integrative conceptual framework encompassing mechanistic phenotypes, host-response diagnostics, and stage-adapted therapeutic combinations is proposed to guide rational intervention across endemic infections and future pandemic preparedness.
    Keywords:  antimicrobial resistance; bacteriophages; chimeric antigen receptor (CAR) immunotherapy; host-directed therapy; infectious diseases; innate immunity; monoclonal antibodies; next-generation antimicrobials; pattern recognition receptors; virulence
    DOI:  https://doi.org/10.3390/biomedicines14030694
  27. J Periodontol. 2026 Mar 23.
       BACKGROUND: Understanding the intricate relationship between sex, age, and the oral microbiome is crucial for deciphering the onset and progression of numerous age-related oral and systemic diseases.
    METHODS: Subgingival plaque was collected from 781 periodontally and systemically healthy females and 160 males spanning 0 to 80 years. 16S amplicon sequencing was performed. 80 million sequences were annotated and analyzed through the QIIME pipeline, principal components analysis (PCA) used for dimensionality reduction, LefSe to identify driver species, beta dispersion to measure inter-subject variability, and machine learning algorithm (RandomForest package in R [RF]) to validate the results. Causal mediation models were implemented to investigate the influence of aging on the male and female microbiomes.
    RESULTS: PCA demonstrated significant class separation based on sex (p < 0.001, permutational multivariate analysis of variance [PERMANOVA]). Males demonstrated higher alpha diversity (p < 0.001, Wilcoxon signed-rank test of the Shannon diversity index), but also higher inter-subject heterogeneity p < 0.001, ANOVA). RF identified males with 0.99 sensitivity, 0.15 specificity, and accuracy of 85%. Age exerted an almost complete mediation effect, with significant differences in the trajectory and pattern of aging between males and females. Females > 30 demonstrated a lower microbial diversity (p < 0.001) and higher levels of Fusobacterium nucleatum (p < 0.001), while the male microbiome remained highly personalized throughout the lifespan, without defined patterns of aging.
    CONCLUSIONS: Sex and age interact to influence the subgingival microbiome. These findings might explain differing disease susceptibilities in either sex, as well as informing personalized prevention and intervention based on age and sex. Further studies using granular -omics approaches are needed to advance our knowledge.
    PLAIN LANGUAGE SUMMARY: Periodontal (gum) diseases are caused by a breakdown in the intricate balance between bacteria that live under the gumline and the local immune response. Since periodontal diseases have been reported to be more common in men than in women, we set out to investigate whether these bacterial communities are intrinsically different between the 2 sexes, and whether these differences are sustained over the lifespan. Using deep-sequencing technology to analyze the microbiomes of 941 individuals, we discovered that sex at birth is indeed a determining factor in the types of bacteria that live under the gums. Aging trajectories and patterns also differ between men and women, with women demonstrating a distinct shift after 30 years of age, and men showing no definite age-based change. These findings have important implications for the cause of periodontitis in either sex, as well as the potential to personalize therapy based on age and sex.
    Keywords:  DNA sequence analysis; age; meta‐taxonomics; oral microbiome; sex; subgingival
    DOI:  https://doi.org/10.1002/jper.70098
  28. Int J Biol Macromol. 2026 Mar 23. pii: S0141-8130(26)01549-7. [Epub ahead of print] 151623
      Anticalins are a class of small, human-derived protein binders engineered from the lipocalin scaffolds and are increasingly discussed as an alternative to nanobodies. With a molecular weight of approximately 20 kD and a fully human protein framework, Anticalins generally exhibit low immunogenicity, high structural stability, and favorable tissue penetration. In this review, we outline key milestones in Anticalin development, summarize commonly used library construction and screening strategies, and provide an overview of their current clinical progress. We further compare Anticalins with nanobodies with respect to structural organization, humanization requirements, and engineering flexibility, highlighting features that arise from their fully human origin. In addition, recent advances in artificial intelligence are briefly discussed in the context of Anticalin research, particularly in structure modeling and affinity optimization, where AI-assisted approaches are beginning to complement established experimental workflows. Taken together, available evidence suggests that Anticalins represent a versatile binder modality with distinct strengths, rather than a direct replacement for nanobodies, and may find particular value in selected therapeutic and diagnostic applications as computational and experimental platforms continue to evolve.
    Keywords:  Anticalin; Artificial intelligence; Bispecific molecule; Drug development; Humanized protein; Lipocalin; Nanobody; Phage display; Protein binder; Targeted therapy
    DOI:  https://doi.org/10.1016/j.ijbiomac.2026.151623
  29. Front Microbiol. 2026 ;17 1768117
       Objective: This study systematically evaluates the current situation, knowledge structure and development trend of bacteriophage-mediated intestinal microbiota regulation research from 2005 to 2024 through literature measurement analysis.
    Method: Retrieve relevant research from the Web of Science core collection, Scopus and PubMed databases. After screening according to inclusion criteria, CiteSpace, VOSviewer, and R-bibliometrix were employed for bibliometric and visualization analysis. This systematically mapped publication trends, collaboration networks among countries/institutions/authors, core journals, and research hotspots.
    Results: Thousands of relevant studies were included. From 2005 to 2024, the number of papers published in microbiology journals showed a step-by-step increase, reaching a peak of 355 articles in 2022. The United States and China are the main contributors. University College Cork in Ireland and San Diego State University in the United States have become core research institutions, and Colin Hill is listed as the most influential author. The Frontiers in Microbiology has published the largest number of papers, and Microbiome and Nature Communications have become platforms for the publication of high-impact research results. The research focus has shifted from the description of early bacteriophage-bacterial binary interaction to exploring the ternary relationship of "bacteriophage-microbiota-host health." In recent years, short-chain fatty acids, microbiota disorders and clinical intervention have become the core research directions. This study included 16 clinical trials on phage-mediated gut microbiota regulation, 14 of which were based on moderate to high-quality clinical evidence, indicating that research design in this field has advanced from the initial observational stage to the intervention verification stage.
    Conclusion: This research systematically sorts out the research progress of 20 years in the field of bacteriophage-mediated intestinal microbiota regulation through the method of literature metrology. The research clearly outlines the evolutionary trajectory of this field from basic description to mechanism exploration to clinical transformation. Future research should focus on the following directions: clarifying the molecular mechanism of the interaction of core diseases, establishing a standardized research framework, and carrying out large-scale multi-center clinical trials to promote the transformation of this field from basic research to clinical application.
    Keywords:  bacteria; bacteriophage; bibliometric analysis; gut microbiota; host health
    DOI:  https://doi.org/10.3389/fmicb.2026.1768117
  30. Int J Infect Dis. 2026 Mar 20. pii: S1201-9712(26)00171-2. [Epub ahead of print] 108536
       BACKGROUND: Effective care for bacterial infections requires both new antibiotics (ABx) to address antimicrobial resistance (AMR) and appropriate diagnostics (Dx) to guide their use. Diagnostics are essential to identify pathogens, determine susceptibility, and support targeted prescribing, including ruling out unnecessary antibiotic use. However, diagnostics are undervalued in the current market, limiting their availability and integration with antibiotic development.
    AIM: To examine the interplay between antibiotics and diagnostics and assess the potential value of coordinated development and partnerships.
    METHODS: This paper analyses the antibiotic and diagnostic development landscape, focusing on market dynamics, regulatory frameworks, and collaboration models involving ABx developers, Dx developers, clinicians, and public-sector stakeholders.
    RESULTS: Antibiotics and diagnostics are rarely developed or introduced in parallel, and available diagnostics often fail to deliver treatment-focused or point-of-care-relevant results. This misalignment hampers the effective deployment of new antibiotics and weakens stewardship. Cross-technology partnerships can improve trial efficiency, enhance market valuation, and support more targeted antibiotic use. Key barriers include fragmented incentives, regulatory misalignment, and financial constraints.
    CONCLUSION: Better alignment between antibiotic and diagnostic development is critical to maximise clinical impact and support resistance monitoring. Public-sector support could help enable effective partnerships and improve patient outcomes.
    Keywords:  Antibiotic-diagnostic co-development; Antimicrobial resistance; Drug-diagnostic partnerships; Precision infection management
    DOI:  https://doi.org/10.1016/j.ijid.2026.108536
  31. J Nanobiotechnology. 2026 Mar 22.
       BACKGROUND: Staphylococcus aureus skin infections represent a persistent clinical challenge owing to their high pathogenicity, multidrug resistance, and biofilm-associated recurrence, which collectively impair antibiotic penetration and exacerbate host inflammation. Emodin, a natural anthraquinone with dual antibacterial and anti-inflammatory activities, has shown therapeutic promise but suffers from poor solubility, rapid clearance, and a lack of pathogen specificity, limiting its translational potential. Here, we developed a multifunctional nanoplatform composed of tetrahedral framework nucleic acids (tFNAs), in which Emodin was noncovalently loaded onto a DNA scaffold to enable sustained release, and a Staphylococcus aureus-specific aptamer was displayed to enable targeted bacterial recognition. Notably, this aptamer-guided design is pathogen oriented, aiming for bacteria-associated enrichment in infected wounds rather than targeting host inflammatory markers or specific immune cell subsets.
    RESULTS: This system markedly potentiated the antibacterial efficacy of Emodin against methicillin-resistant S. aureus (MRSA), significantly inhibited biofilm formation, and disrupted mature biofilms. In murine infection models, the Apt-tFNAs-Emo reduced the bacterial burden, alleviated oxidative stress and TLR4/NF-κB activation, suppressed proinflammatory cytokine production, and accelerated wound healing by restoring collagen deposition and epidermal architecture.
    CONCLUSIONS: Overall, this study establishes an aptamer-targeted nucleic acid nanoplatform that integrates antimicrobial delivery, biofilm disruption, and host immunomodulation, offering a promising therapeutic strategy for multidrug-resistant S. aureus skin infections.
    Keywords:   Staphylococcus aureus ; Biofilm disruption; Emodin; Immunomodulation; Tetrahedral framework nucleic acids
    DOI:  https://doi.org/10.1186/s12951-026-04278-5
  32. Pathogens. 2026 Mar 06. pii: 288. [Epub ahead of print]15(3):
      Antimicrobial resistance is a growing global health crisis, with projections estimating up to 10 million deaths annually and more than 130 million hospitalizations attributable to resistant infections. Resistance emerges through microbial adaptation to sustained antimicrobial pressure, resulting in genetic and phenotypic mechanisms such as target mutations, enzymatic drug inactivation, efflux pump activation, biofilm formation, and metabolic adaptation that drive the emergence of multidrug-resistant pathogens and limit effective therapy. This bibliometric review analyzes the MEDLINE-indexed articles to characterize patient health and age factors, resistance mechanisms, pathogen types, and therapeutic strategies associated with antimicrobial resistance. The findings demonstrate that antimicrobial resistance is disproportionately reported among adults and chemotherapy-treated patients, with transmitted resistance emerging as the dominant driver, emerging from antibiotic misuse or overuse. Despite extensive mechanistic knowledge, treatment remains largely focused on escalation to newer antibiotics, while combination and adjunctive therapies are less commonly reported. These results analyze 308,290 studies to identify patient-related contexts, resistance mechanisms, pathogens, and therapeutic strategies.
    Keywords:  antibacterial; antibiotics; fungi; hygiene; infectious diseases; parasites; viruses
    DOI:  https://doi.org/10.3390/pathogens15030288
  33. Crit Rev Clin Lab Sci. 2026 Mar 25. 1-33
      Research on the microbiome is reshaping the conceptual foundations of inflammatory diseases. As a dynamic component of the host ecosystem, microbial communities collectively influence inflammatory responses and homeostatic balance through their metabolites, structural signals, and interactions with immune pathways. Dysbiosis can amplify immune activation and metabolic disturbances, leading to persistent inflammation, whereas specific commensal taxa and their metabolites possess the capacity to suppress excessive immune responses and restore homeostasis. This bidirectional regulatory capacity positions the microbiome as a central node that both drives and modulates inflammatory networks. Multi-omics investigations have delineated the systemic architecture of microbe-host interactions, revealing cross-system axes such as the gut-brain, gut-liver, and skin-gut pathways that constitute a signaling framework integrating inflammation and immunity, thereby reshaping our understanding of disease pathogenesis. Within this framework, inflammation is redefined as an adaptive strategy for maintaining systemic stability rather than merely a singular pathological reaction. Therapeutic approaches including fecal microbiota transplantation (FMT), engineered microbial strains, and interventions targeting metabolic signaling are propelling microecological medicine into an era of precision modulation. As systems biology converges with spatial omics, research on the microbiome is shifting from descriptive pathology toward mechanistic control, establishing it as a critical nexus linking immunity, metabolism, and disease evolution. This transformation heralds a paradigm shift in medicine from merely "suppressing inflammation" to actively "reconstructing ecological order."
    Keywords:  Microbiome; dysbiosis; immune homeostasis; inflammatory diseases; microecological interventions
    DOI:  https://doi.org/10.1080/10408363.2026.2637106
  34. Arq Gastroenterol. 2026 ;pii: S0004-28032026000100203. [Epub ahead of print]63 e25087
       OBJECTIVE: This study is a bibliometric analysis of scientific publications reporting the beneficial effects of gut microbiota modulation by probiotics and/or prebiotics on colorectal cancer.
    METHODS: This study adhered to the PRISMA guidelines and focused on English peer-reviewed research articles published between 2020 and 2025, as indexed in Google Scholar and PubMed. Search terms included "Colorectal Cancer", "Colon Cancer", "Colorectal Carcinoma", "Colon Carcinoma" and "Gut Microbiota". A total of 116 studies were selected and manually reviewed, taking into account the inclusion and exclusion criteria.
    RESULTS: The bibliometric analysis of 37 studies revealed that China leads research efforts, primarily focusing on prebiotics (70.3%), such as dietary fibres, while probiotic-focused studies are limited (24.3%) due to practical challenges. Although the combined use of prebiotics and probiotics (2.7%) is theoretically beneficial, their practical application remains complicated. The trend in the literature aligns with a growing interest in traditional medicine and functional foods, but annual publication rates have declined, with only three papers from 2025 (30.8%). Despite recognising microbial diversity, the number of probiotic-based studies is low, with Clostridium butyricum being the most prevalent species.
    CONCLUSION: Overall, this analysis underscores the critical role of gut microbiota in CRC treatment and the potential of natural compounds, while highlighting the need for further research. Further research is essential to deepen our understanding of gut microbiota dynamics and optimise therapeutic approaches for patients with CRC.
    DOI:  https://doi.org/10.1590/S0004-2803.24612025-087
  35. ERJ Open Res. 2026 Mar;pii: 00373-2025. [Epub ahead of print]12(2):
    ENHANCE-CF study group
      ENHANCE is a multicentre, longitudinal study examining the natural history of early cystic fibrosis (CF) disease manifestations in children. We hypothesise that the prevalence, presentation and natural history of disease manifestations of CF in young children will change significantly in the next decade with advances in the understanding and treatment of CF, including the use of therapies aimed at improving CFTR function. The study has been co-developed with the CF community, in order to try to answer questions of key importance to people with CF and their caregivers. The study will longitudinally monitor lung health using nitrogen multiple breath washout testing and spirometry, lung structure using spirometry-controlled computed tomography scanning, gastrointestinal health using gut microbiome, gut inflammation and abdominal symptom scores, pancreatic function using faecal elastase, liver function using liver blood tests and liver ultrasound, and sweat chloride. Mental health will be longitudinally assessed using questionnaires for mood (PROMIS, GAD-7), quality of life (CFQ-R) and psychosocial functioning (Pediatric Symptom Checklist). There are three cohorts in the study: infants with CF diagnosed by newborn screening (n=250), children aged 0-6 years and currently attending CF centres (n=200) and healthy newborn infant controls (100). The study will be conducted over 5 years in the first phase with a plan to extend through further phases in the future. We envisage that the study will provide important evidence to enable healthcare staff and families to guide the care of children with CF in the future.
    DOI:  https://doi.org/10.1183/23120541.00373-2025
  36. Infect Drug Resist. 2026 ;19 573735
      Antimicrobial resistance (AMR) is one of the major threats to global health, with a complex and diverse underlying mechanism. Vaccines reduce the dependence on antimicrobial agents by preventing and treating bacterial and viral infections, as well as secondary infections caused by both, thereby lowering the risk of AMR. Unlike traditional antibiotics, bacterial vaccines trigger a long-lasting immune response that not only prevents bacterial infections but also inhibits the spread of resistant strains. They show significant advantages in reducing antibiotic use and lowering resistance risks. However, the development of bacterial vaccines faces several challenges, including the diversity of bacterial antigens, rapid evolution, and the difficulty of achieving broad-spectrum immune protection. Despite these challenges, advancements in vaccine technology and the optimization of delivery systems are making the application prospects of bacterial vaccines in combating resistant strains increasingly promising. We sequentially discuss resistance mechanisms, existing and emerging vaccine platforms, enabling technologies, and future perspectives.
    Keywords:  antimicrobial resistance; bacterial infections; bacterial vaccines; challenges; technology
    DOI:  https://doi.org/10.2147/IDR.S573735
  37. Nat Commun. 2026 Mar 24.
      Escherichia coli (E. coli) strains expressing the capsule serotype K1 (E. coli K1) are a prevalent cause of neonatal sepsis and meningitis. The gut microbiota of healthy adults is a natural reservoir of E. coli K1, from which it can spread to extra-intestinal sites or be transmitted from mother to infant during birth. Accordingly, shifting gut colonization from potentially pathogenic E. coli strains to more benign strains could reduce the risk of disease. Here, we leverage selective pressures exerted by bacteriophage and mucosal antibodies to limit gut colonization by E. coli K1 and prevent its transmission. K1-specific bacteriophages (phages) rapidly drive a within-host evolution of capsule-less mutants with exposed surface O-antigens. These mutants become susceptible to vaccine-induced intestinal IgA targeting the bacterial O-antigen, allowing competitive exclusion by the probiotic strain E. coli Nissle. In a murine vertical transmission model, 77% of pups were protected from transmission of E. coli K1 when the mother was vaccinated and treated with phages, whereas E. coli K1 was detected in most pups by day 10 of life when the mother received vaccination or phage therapy alone. Although the high diversity of E. coli makes generalization challenging, combining vaccination with phage-steering represents a promising approach for further exploration in eliminating infectious reservoirs.
    DOI:  https://doi.org/10.1038/s41467-026-70808-2
  38. J Clin Med. 2026 Mar 23. pii: 2443. [Epub ahead of print]15(6):
      Over the past decade, the therapeutic landscape of cystic fibrosis (CF) has undergone a historic transformation; once considered a progressive, life-limiting multisystem disease treated exclusively with symptomatic therapies, CF has entered the era of mutation-specific treatment, for Contribution 1 [...].
    DOI:  https://doi.org/10.3390/jcm15062443
  39. J Clin Med. 2026 Mar 22. pii: 2434. [Epub ahead of print]15(6):
      Background/Objectives: Psoriasis and periodontitis share inflammatory pathways. Current evidence suggests a bidirectional non-causal relation. However, the evidence on the effects of periodontal treatment on psoriasis outcomes (severity, inflammatory markers, quality of life) is limited. This study aims to synthetize the available clinical and preclinical evidence of periodontal treatment effects on psoriasis outcomes, in patients with comorbid psoriasis and periodontitis (CRD420261298145). Methods: Several databases (PubMed, WebOfScience, ScienceDirect, ProQuest and GoogleScholar) were searched for relevant articles, without language or time restrictions. We included randomised and non-randomised clinical studies on humans, and controlled animal experiments. Interventions included periodontal treatment (surgical and non-surgical). Outcomes were the Psoriasis Area and Severity Index and dermatology-specific quality of life scores; secondary outcomes included inflammatory biomarkers and periodontal parameters. Studies were screened in duplicate, data extracted independently and risk of bias was assessed using Cochrane RoB 2, ROBINS I, NOS and SYRCLE. Results: A total of five studies were included in this systematic review (four clinical studies and one preclinical studies). Three studies directly assessed post-treatment psoriasis outcomes, with two studies investigating inflammation mediators as secondary outcomes. Two studies directly assessed PASI (Psoriasis Area and Severity Index) modifications, both studies confirming PASI scores decreasing post-periodontal treatment; one study also reported DLQI (Dermatology Life Quality Index). Typical follow-up durations ranged from 8 to 10 weeks for interventional studies, to 5 years for one cohort study. Conclusions: Although momentarily limited by the small number of available studies, the results of this review suggest that periodontal treatment may be associated with improvements in psoriasis outcomes. Further studies on larger samples, with longer follow-up periods would be necessary to confirm and possibly strengthen the existing results.
    Keywords:  non-surgical periodontal treatment; palmoplantar pustulosis; periodontitis; psoriasis; systematic review
    DOI:  https://doi.org/10.3390/jcm15062434
  40. Prog Mol Subcell Biol. 2026 ;62 333-366
      Omics technologies have revolutionized research across diverse fields, and their increasing use in microbiology has provided new opportunities for understanding microbial life. These methods enable detailed investigation of the molecular biology of individual organisms as well as the complex interactions within microbial communities. In this chapter, we describe key single-organism omics approaches, including genomics, transcriptomics, proteomics, and metabolomics, as well as meta-omics techniques such as metagenomics, metatranscriptomics, metaproteomics, and meta-metabolomics. We also discuss integrative multi-omics strategies for studying microbial ecosystems. For each omics method, we outline its main features, experimental and bioinformatic workflows, major applications, and commonly used computational tools, thereby providing a practical guide for researchers aiming to explore microbial structure, function and interactions at multiple molecular levels.
    Keywords:  Genomics; Meta-metabolomics; Metabolomics; Metagenomics; Metaproteomics; Metatranscriptomics; Proteomics; Transcriptomics
    DOI:  https://doi.org/10.1007/978-3-032-11438-9_10
  41. Medicina (Kaunas). 2026 Feb 28. pii: 462. [Epub ahead of print]62(3):
      Background and Objectives: Pseudomonas aeruginosa is a versatile, opportunistic pathogen responsible for a wide spectrum of infections, particularly in immunocompromised patients and those with disrupted epithelial barriers and chronic respiratory conditions. Its clinical significance is amplified by intrinsic and acquired antibiotic resistance, contributing to high mortality rates and treatment challenges. The bacterium's pathogenic success stems from a multifaceted repertoire of virulence factors, including adhesins, pili, fimbriae, flagella, exopolysaccharides, biofilm-associated proteins, secreted toxins, proteases, lipases, phospholipases, rhamnolipids and redox-active metabolites. These factors are tightly regulated through complex networks, such as quorum sensing and c-di-GMP signaling, enabling dynamic adaptation to host environments and modulation of acute and chronic infection phenotypes. Biofilm formation and nutrient acquisition strategies further support survival in resource-limited conditions and protect against immune clearance and antibiotic pressure. Antibiotic resistance in P. aeruginosa limits therapeutic options. In addition, it may indirectly enhance virulence through modulation of stress responses and quorum sensing. P. aeruginosa's pathogenicity emerges from the synergy between traditional virulence determinants and adaptive survival strategies, supporting long-term persistence, chronic infection, and resistance to host immunity and therapy. Materials and Methods: This narrative review is based on a comprehensive analysis of recent peer-reviewed literature focusing on virulence regulation, biofilm formation, nutrient acquisition strategies, and the interplay between antibiotic resistance and pathogenicity. Results: The reviewed evidence indicates that virulence expression in P. aeruginosa is highly dynamic and context-dependent, with regulatory networks integrating environmental signals to fine-tune pathogenic responses. A consistent finding across studies is the central role of biofilm-associated adaption in promoting persistence and antimicrobial tolerance. Moreover, the interaction between resistance mechanisms and global regulatory pathways appears to enhance bacterial fitness and long-term survival within the host. Conclusions: A deeper understanding of these interconnected mechanisms may facilitate the development of more effective anti-virulence and therapeutic strategies.
    Keywords:  Pseudomonas aeruginosa; antibiotic resistance; biofilm; chronic infection; quorum sensing; virulence factors
    DOI:  https://doi.org/10.3390/medicina62030462
  42. Front Cell Infect Microbiol. 2026 ;16 1780396
       Background: Retained metallic foreign bodies can lead to implant-associated wound infections through bacterial colonization and biofilm formation. We report a case of a wound infection associated with a retained metallic fragment caused by Staphylococcus arlettae (S. arlettae) and evaluate the organism's early biofilm formation on common implant metals.
    Case presentation: A 33-year-old man sustained a crush injury to his right hand and forearm, resulting in extensive soft-tissue damage and vascular injury. Emergency surgical management included meticulous debridement and vascular reconstruction. Postoperatively, purulent wound infection was effectively managed following microbiological identification of S. arlettae and antibiotic susceptibility-guided therapy. The treatment regimen involved serial debridement along with stepwise adjustments in antimicrobial dosing. Follow-up revealed that the patient's hand function had recovered well.
    Methods and results: In vitro assays were conducted to compare early bacterial attachment and biofilm formation of the clinical S. arlettae isolate on stainless steel 304 (SS304), stainless steel 316 (SS316), and titanium alloy (TC4). The results revealed material-dependent differences in initial adherence as well as early biofilm development, establishing a link between implant surface properties and bacterial colonization propensity.
    Conclusions: This case underscores the clinical significance of retained metallic fragments as potential foci for S. arlettae infection, emphasizing the necessity for prompt debridement, targeted antimicrobial therapy, and consideration of implant material properties. In vitro evidence demonstrating differential biofilm behavior on SS304, SS316, and TC4 has important implications for surgical decision-making, selection of implants, management of wounds, and prophylactic antibiotic strategies aimed at mitigating implant-associated infections.
    Keywords:  Staphylococcus arlettae; antibacterial resistance; biofilm; metal characterization; wound infection
    DOI:  https://doi.org/10.3389/fcimb.2026.1780396
  43. J Cyst Fibros. 2026 Mar 24. pii: S1569-1993(26)00081-0. [Epub ahead of print]
       BACKGROUND: Breath profile analysis of volatile organic compounds (VOCs) by electronic nose (eNose) technology can distinguish between healthy individuals and people with cystic fibrosis (pwCF). It remains, however, unclear whether CFTR modulator therapy, that corrects the underlying defect in treated pwCF, alters the exhaled breath profiles.
    METHODS: In this prospective longitudinal study, eNose-derived exhaled breath profiles were obtained using the SpiroNose® (Breathomix, Leiden, The Netherlands) from 61 CF children before starting therapy with elexacaftor/tezacaftor/ivacaftor (ETI), and at follow-up visits less than 3 and more than 6 months after ETI initiation. Routine clinical outcomes and airway microbiology were assessed at all visits. Twenty-six healthy controls provided single measurements. Longitudinal SpiroNose sensor data were analyzed using linear mixed-effects models and permutational multivariate analysis of variance (PERMANOVA), and exploratory mixed-effects models to test for associations with Staphylococcus aureus (SA) airway infection and clearance.
    RESULTS: ETI led to improved sweat chloride concentrations, pulmonary function (ppFEV1) and BMI, but no significant changes in SpiroNose sensor signals were observed during follow-up. SpiroNose sensor signals reliably discriminated healthy controls from CF children at baseline and at follow-up on ETI, with consistent differences in multiple SpiroNose sensors. SA airway infection was captured (sensor S7), whereas SA clearance did not result in measurable changes in SpiroNose signals.
    CONCLUSIONS: CFTR modulator therapy with ETI does not significantly alter eNose-derived VOC breath profiles in children with CF. The ability of the eNose to distinguish CF from healthy controls remains unchanged after ETI initiation.
    Keywords:  CFTR modulator treatment; Cystic fibrosis; Electronic nose; Respiratory disease; Respiratory infections; Volatile organic compounds
    DOI:  https://doi.org/10.1016/j.jcf.2026.03.014